ARTICLE | Distillery Therapeutics
Oligoadenylate-conjugated benzimidazole-based miR-210 inhibitor for breast cancer
June 7, 2019 10:46 PM UTC
INDICATION: Breast cancer...
BCIQ Company Profiles
BCIQ Target Profiles
INDICATION: Breast cancer...
BCIQ Company Profiles
BCIQ Target Profiles